<DOC>
	<DOCNO>NCT01915758</DOCNO>
	<brief_summary>This single-center , evaluator-blinded , randomize , placebo ( vehicle ) -controlled phase I study evaluate photoallergic potential Clindamycin-Tretinoin Gel . The design consist follow period : screening , induction , rest , challenge , rechallenge ( indicate ) . Induction visit 1 occur within 5 day screen visit 2 . The study expect enroll approximately 62 healthy adult volunteer . Subjects receive repeat 24-hour study patch application ; patch removal , site irradiate ultraviolet B light ( UVB ) visible light ( VIS ) induction period ( consist 6 consecutive induction phase ) , ultraviolet A light ( UVA ) / UVB VIS challenge rechallenge period . Each application site observe approximately 1 , 24 , 48 , 72 hour later sign inflammation .</brief_summary>
	<brief_title>W0265-104 : A Single-Center , Evaluator-Blinded , Randomized , Placebo-Controlled , Phase 1 Clinical Trial Evaluating Photoallergic Potential Topically Applied Clindamycin Phosphate 1.0 % Tretinoin 0.025 % ( CT Gel ) Healthy Volunteers</brief_title>
	<detailed_description>This single-center , evaluator-blinded , randomize , placebo ( vehicle ) -controlled phase I study evaluate photoallergic potential Clindamycin-Tretinoin Gel . The design consist follow period : screening , induction , rest , challenge , rechallenge ( indicate ) . Induction visit 1 occur within 5 day screen visit 2 . The study expect enroll approximately 62 healthy adult volunteer . Subjects receive repeat 24-hour study patch application ; patch removal , site irradiate ultraviolet B light ( UVB ) visible light ( VIS ) induction period ( consist 6 consecutive induction phase ) , ultraviolet A light ( UVA ) / UVB VIS challenge rechallenge period . Each application site observe approximately 1 , 24 , 48 , 72 hour later sign inflammation .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>The capability understand provide sign dated write voluntary inform consent ( local national authorization requirement ) protocolspecific procedure perform . Male female subject age 18 65 year , inclusive , time consent . The ability complete study comply study instruction . Possessed Fitzpatrick skin type I ( always burn easily ; never tan ) , II ( always burn easily ; tan minimally ) , III ( burn moderately , tan gradually ) would interfere read skin response . Determination skin type base sunburn tan history , well subject ' opinion response first 30 45 minute sun exposure . Sexually active female childbearing potential agree use medically acceptable method contraception receive protocolassigned product . A woman childbearing potential define one biologically capable become pregnant , include perimenopausal woman le 2 year last menses . Acceptable contraceptive method include follow : Hormonal contraception , include oral , injectable , implantable method start least 2 month prior screen . If hormonal contraception start less 2 month prior screen , form nonhormonal contraception add third continuous month hormonal contraception complete . Two form nonhormonal contraception , include intrauterine device properly use barrier method ( eg , male female condom , diaphragm , cervical cap ) . Subjects surgical sterilization , include tubal ligation partner 's vasectomy , use form nonhormonal contraception . A barrier method sterilization plus spermatocide acceptable . Women currently sexually active lactate agree use medically accept method contraception become sexually active participate study . Currently diagnose cancer previous history cancer , include skin cancer , severe photodamaged skin . Severe photodamaged skin characterize yellowgray color , wrinkle visible normal skin , prior skin malignancy . Female subject pregnant , attempt become pregnant , breast feeding . Received investigational drug within 4 week study day 1 schedule receive investigational drug study product study . Used contraindicated prescription drug within 4 week 5 halflives , whichever longer , first dose study product , unless agree clinically relevant principal investigator project physician . Participated previous study study product . Current use medication , opinion investigator , may affect evaluation study product place subject undue risk . Suffered disease condition , opinion investigator , may affect evaluation study product place subject undue risk . Any major illness within 30 day screen examination . Considered immunocompromised use immunosuppressant drug . Clinically relevant history current evidence abuse alcohol drug . History know suspect intolerance ingredient study product ( ie , test comparator product ) , hypoallergenic tape , cotton patch . Clinically relevant history presence respiratory ( include chronic asthma require repetitive drug intervention ) , gastrointestinal , renal , hepatic , hematological , lymphatic , immunological , dermatological , connective tissue diseases disorder . Considered unable unlikely attend necessary visit . History severe reaction exposure sunlight , include previous experience photoallergy , solar urticaria , polymorphous light eruption , photoexacerbated systemic disease . Current use expect use photosensitize medication ( overthe counter prescription ) , herbal supplement , use know photosensitize material . Clinically significant skin disease contraindicate participation interfere test site evaluation , include psoriasis , eczema , atopic dermatitis , acne , dyplastic nevus , skin pathology . Investigator inability evaluate skin around potential test site due sunburn , unevenness skin tone , tattoo , scar , excessive hair , freckle , birthmark , mole , skin abnormality . Used topical medication ( eg , corticosteroid immunosuppressive ) potential test site within last 7 day prior screen visit 1 . Currently receive allergy injection , due receive injection , within 7 day prior screen visit 1 , expect begin injection study participation . Used antihistamine prescription antiinflammatory drug within 72 hour day 1 visit . Permitted exception acetaminophen recommend dos aspirin dos le 81 mg/day . Participated patch test study irritation sensitization test involve ultraviolet exposure within last 4 week . Employees CRO sponsor involve study , immediate family member ( partner , offspring , parent , sibling , sibling 's offspring ) employee involve study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>